4586.T
The company operates in the Pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.
Business. The company operates in the Pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the Pharmaceuticals industry, primarily generating revenue through the development, production, and sale of pharmaceutical products.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥175,466.9 million, representing 81.3% of total assets. The liquidity FPT (free cash flow to total assets) is negative at -46.7%, indicating a cash outflow from operations. The current ratio of 23.62 suggests a robust short-term liquidity buffer, with no long-term debt outstanding.
Profitability metrics are severely negative, with a net loss of ¥93,737.2 million and an operating loss of ¥92,959.8 million. Return on equity (ROE) is -45.75%, and return on assets (ROA) is -43.45%, both significantly below industry norms. Gross profit margin is 99.1%, but this is offset by high operating expenses, leading to a negative operating margin of -72.6%.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segmentation data limits visibility into regional exposure and potential revenue concentration risks.
Growth trajectory is negative, with a net loss in the most recent fiscal year. No forward-looking revenue growth estimates are available, and the company's operating cash flow is negative at -¥888.1 million. Capital expenditures are modest at -¥82.75 million, suggesting limited investment in growth.
Risk factors include a high probability of continued losses, with no immediate liquidity or dilution flags detected. The company has no long-term debt, but its negative free cash flow and operating cash flow raise concerns about long-term sustainability. No dilution sources were identified in recent filings.
Recent events include a reported net loss of ¥93,737.2 million and a revenue of ¥128,084 million. Analyst estimates align with reported figures, with no significant deviations in EPS or revenue expectations.
- The company has a strong liquidity position with ¥175,466.9 million in cash and equivalents.
- Profitability is severely negative, with a net loss of ¥93,737.2 million and an ROE of -45.75%.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- Growth trajectory is negative, with no forward-looking revenue growth estimates available.
- No immediate liquidity or dilution risks are flagged, but continued losses raise concerns about long-term sustainability.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- 4586.T Market data — financials · 2026-05-26
- Medrx Co Ltd Market data — analyst estimates · 2026-05-26